Request for Covid-19 Impact Assessment of this Report
Canker sores are caused by an underlying auto-immune condition called aphthous stomatitis. In addition, certain hormonal changes, such as increased or reduced level of certain hormones, can be another cause of canker sores (aphthous ulcers) on the tongue, mouth or lips. If a person has aphtous stomatitis, he will most likely have canker sores on a frequent basis. It is estimated that up to 20% of persons in the UK are affected by this. Mouth ulcers and canker sores are very identical and may be controlled and treated in the same way. In 2019, according to National Health Portal (NHP) of India, aphthous stomatitis or canker sores affect approximately 20% of the general population and they are slightly more common in girls and women.
The growth of the global mouth ulcers treatment market is majorly driven by higher prevalence of mouth ulcers due to increased use of chemicals in food, including citrus or acidic fruits and vegetables (such as lemons, oranges, pineapples, apples, figs, tomatoes, strawberries), oral products, such as toothpaste, rise in anxiety and stress, and tobacco use. Furthermore, due to increasing oral hygiene and mouth infection treatment awareness, rising adoption of pharmaceuticals as a treatment option and a significant rise in the count of geriatric population also contribute to the market growth.
Smoking cessation though beneficial for health, mouth ulcers are its unfortunate side effect. According to Centers for Disease Control and Prevention (CDC) in 2019, 57.8% of youth (middle and high school students) who currently used tobacco products (3.3 million) reported that they were seriously thinking about quitting the use of all tobacco products. Thus, this gave rise to increased cases of mouth ulcers and an opportunity for the companies to invest in the mouth ulcers treatment market.
According to World Health Organization (WHO) in 2021, tobacco kills more than 8 million people each year and more than 7 million of those deaths are a result of direct tobacco use while around 1.2 million are the result of non-smokers being exposed to second-hand smoke. Over 80% of the world's 1.3 billion tobacco users live in low and middle income countries. Thus, increasing the occurrence of mouth ulcers and further driving the market significantly.
The American Academy of Oral Medicine (AAOM) affirmed that patients with oral lichen planus (inflammatory condition that affects mucous membranes inside your mouth) has an increased risk of developing oral cancer and requires careful management and monitoring by appropriately trained clinicians. Noma is a severe gangrenous disease that affects the mouth and face and primarily affects children aged 2 to 6 years who are malnourished, infected with infectious disease, living in extreme poverty with poor oral hygiene, and/or have weakened immune systems. It begins as a soft tissue lesion (a sore) of the gums, deep within the mouth. Recurrent aphthous ulcers are the most common oral mucosal disease in North America. They affect 20% of the population, with the incidence rising to more than 50% in certain groups of students in professional schools. According to WHO in March 2020, oral diseases pose a major health burden for many countries and affect people throughout their lifetime, causing pain, discomfort, disfigurement and even death. It is estimated that oral diseases affect nearly 3.5 billion people.
In addition, increased consciousness for dental and oral hygiene, availability of different treatments, rapid healing and easy to use products for treating ulcers are the major factors that drive the global mouth ulcers treatment market. Moreover, the emergence of innovative products, technical advancements in the field of dental care, and increasing use of pharmaceuticals for oral treatment are expected to enhance the demand for mouth ulcers treatment. Thus, advancements in technology in the healthcare sector and rise in prevalence of mouth ulcers due to inclination towards healthy lifestyle are expected to propel the growth of the market.
On the contrary, presence of substitute traditional treatments, limited accessibility to pharmaceuticals in developing countries, and side effects associated with the use of mouth ulcer treatment products are curtailing the market growth. Conversely, rise in adoption of affordable treatments in developing as well as under developed countries, by increasing government initiatives, reduced side effects, and self-awareness for healthy lifestyle accordingly encourages many key players to enter into the competition, thus creating a lucrative growth opportunity for the mouth ulcers treatment market.
The global mouth ulcers treatment market is segmented on the basis of drug class, formulation type, indication, and region. On the basis of drug class, the market is categorized into analgesics and corticosteroids, antihistamine, antimicrobial, and anesthetic. By formulation type, the market is divided into sprays, mouthwash, gels, and lozenges. By indication, the market is classified into aphthous stomatitis, oral lichen planus, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global mouth ulcers treatment market include Blistex Inc., Bristol-Myers Squibb Company, Church & Dwight Co, Inc., Colgate Palmolive Company, Dr. Reddy’s, GlaxoSmithKline, plc., Patterson Dental Supply, Inc., Pfizer Inc., Prince Care Pharma Private Limited, and 3M.
KEY BENEFITS FOR STAKEHOLDERS
• This report provides an extensive analysis of the current and emerging market trends and dynamics in the global mouth ulcers treatment market to identify the prevailing opportunities.
• This study presents the competitive landscape of the global market to predict the competitive environment across geographies.
• Comprehensive analysis of factors that drive and restrict the market growth is provided.
• Region- & country-wise analysis is provided to understand the market trends and dynamics.
KEY MARKET SEGMENTS
By Drug Class
o Analgesics and corticosteroids
o Antihistamine
o Antimicrobial
o Anesthetic
By Formulation
o Sprays
o Mouthwash
o Gels
o Lozenges
By Indication
o Aphthous Stomatitis
o Oral Lichen Planus
o Others
By Region
o North America
U.S.
Canada
Mexico
o Europe
Germany
France
UK
Italy
Spain
Rest of Europe
o Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
o LAMEA
Brazil
South Africa
Saudi Arabia
Rest of LAMEA
KEY MARKET PLAYERS
• Blistex Inc.
• Bristol-Myers Squibb Company
• Church & Dwight Co, Inc.,
• Colgate Palmolive Company,
• Dr. Reddy’s Laboratories Ltd.
• GlaxoSmithKline, plc.,
• Patterson Companies, Inc.,
• Pfizer Inc.,
• Prince Care Pharma Private Limited
• 3M
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in prevalence of mouth ulcers
3.5.1.2.Rising dental and oral hygiene awareness
3.5.1.3.Increase in overall population
3.5.2.Restraint
3.5.2.1.Lack of awareness and availability of traditional substitutes
3.5.3.Opportunity
3.5.3.1.Growing opportunities in emerging market due to innovative products
3.5.4.Impact analysis
3.6.Impact analysis of COVID-19 on the mouth ulcers treatment market
CHAPTER 4:MOUTH ULCERS TREATMENT MARKET, BY DRUG CLASS
4.1.Overview
4.1.1.Market size and forecast
4.2.Analgesics and Corticosteroids
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.2.4.Market analysis, by indication
4.3.Antihistamine
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.3.4.Market analysis, by indication
4.4.Antimicrobial
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.4.4.Market analysis, by indication
4.5.Anesthetic
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
4.5.4.Market analysis, by indication
CHAPTER 5:MOUTH ULCERS TREATMENT MARKET, BY FORMULATION TYPE
5.1.Overview
5.1.1.Market size and forecast
5.2.Sprays
5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country
5.3.Mouthwash
5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by region
5.3.3.Market analysis, by country
5.4.Gels
5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast, by region
5.4.3.Market analysis, by country
5.5.Lozenges
5.5.1.Key market trends, growth factors, and opportunities
5.5.2.Market size and forecast, by region
5.5.3.Market analysis, by country
CHAPTER 6:MOUTH ULCERS TREATMENT MARKET, BY INDICATION
6.1.Overview
6.1.1.Market size and forecast
6.2.Aphthous Stomatitis
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by region
6.2.3.Market analysis, by country
6.3.Oral Lichen Planus
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by region
6.3.3.Market analysis, by country
6.4.Others
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by region
6.4.3.Market analysis, by country
CHAPTER 7:MOUTH ULCERS TREATMENT MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America Mouth Ulcers Treatment market, by drug class
7.2.3.North America Mouth Ulcers Treatment market, by formulation type
7.2.4.North America Mouth Ulcers Treatment market, by indication
7.2.5.Market size and forecast, by country
7.2.5.1.U.S.
7.2.5.1.1.U.S. Mouth Ulcers Treatment market, by drug class
7.2.5.1.2.U.S. Mouth Ulcers Treatment market, by formulation type
7.2.5.1.3.U.S. Mouth Ulcers Treatment market, by indication
7.2.5.2.Canada
7.2.5.2.1.Canada Mouth Ulcers Treatment market, by drug class
7.2.5.2.2.Canada Mouth Ulcers Treatment market, by formulation type
7.2.5.2.3.Canada Mouth Ulcers Treatment market, by indication
7.2.5.3.Mexico
7.2.5.3.1.Mexico Mouth Ulcers Treatment market, by drug class
7.2.5.3.2.Mexico Mouth Ulcers Treatment market, by formulation type
7.2.5.3.3.Mexico Mouth Ulcers Treatment market, by indication
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe Mouth Ulcers Treatment market, by drug class
7.3.3.Europe Mouth Ulcers Treatment market, by formulation type
7.3.4.Europe Mouth Ulcers Treatment market, by indication
7.3.5.Market size and forecast, by country
7.3.5.1.Germany
7.3.5.1.1.Germany Mouth Ulcers Treatment market, by drug class
7.3.5.1.2.Germany Mouth Ulcers Treatment market, by formulation type
7.3.5.1.3.Germany Mouth Ulcers Treatment market, by indication
7.3.5.2.France
7.3.5.2.1.France Mouth Ulcers Treatment market, by drug class
7.3.5.2.2.France Mouth Ulcers Treatment market, by formulation type
7.3.5.2.3.France Mouth Ulcers Treatment market, by indication
7.3.5.3.UK
7.3.5.3.1.UK Mouth Ulcers Treatment market, by drug class
7.3.5.3.2.UK Mouth Ulcers Treatment market, by formulation type
7.3.5.3.3.UK Mouth Ulcers Treatment market, by indication
7.3.5.4.Italy
7.3.5.4.1.Italy Mouth Ulcers Treatment market, by drug class
7.3.5.4.2.Italy Mouth Ulcers Treatment market, by formulation type
7.3.5.4.3.Italy Mouth Ulcers Treatment market, by indication
7.3.5.5.Spain
7.3.5.5.1.Spain Mouth Ulcers Treatment market, by drug class
7.3.5.5.2.Spain Mouth Ulcers Treatment market, by formulation type
7.3.5.5.3.Spain Mouth Ulcers Treatment market, by indication
7.3.5.6.Rest of Europe
7.3.5.6.1.Rest of Europe Mouth Ulcers Treatment market, by drug class
7.3.5.6.2.Rest of Europe Mouth Ulcers Treatment market, by formulation type
7.3.5.6.3.Rest of Europe Mouth Ulcers Treatment market, by indication
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific Mouth Ulcers Treatment market, by drug class
7.4.3.Asia-Pacific Mouth Ulcers Treatment market, by formulation type
7.4.4.Asia-Pacific Mouth Ulcers Treatment market, by indication
7.4.5.Market size and forecast, by country
7.4.5.1.Japan
7.4.5.1.1.Japan Mouth Ulcers Treatment market, by drug class
7.4.5.1.2.Japan Mouth Ulcers Treatment market, by formulation type
7.4.5.1.3.Japan Mouth Ulcers Treatment market, by indication
7.4.5.2.China
7.4.5.2.1.China Mouth Ulcers Treatment market, by drug class
7.4.5.2.2.China Mouth Ulcers Treatment market, by formulation type
7.4.5.2.3.China Mouth Ulcers Treatment market, by indication
7.4.5.3.Australia
7.4.5.3.1.Australia Mouth Ulcers Treatment market, by drug class
7.4.5.3.2.Australia Mouth Ulcers Treatment market, by formulation type
7.4.5.3.3.Australia Mouth Ulcers Treatment market, by indication
7.4.5.4.India
7.4.5.4.1.India Mouth Ulcers Treatment market, by drug class
7.4.5.4.2.India Mouth Ulcers Treatment market, by formulation type
7.4.5.4.3.India Mouth Ulcers Treatment market, by indication
7.4.5.5.South Korea
7.4.5.5.1.South Korea Mouth Ulcers Treatment market, by drug class
7.4.5.5.2.South Korea Mouth Ulcers Treatment market, by formulation type
7.4.5.5.3.South Korea Mouth Ulcers Treatment market, by indication
7.4.5.6.Rest of Asia-Pacific
7.4.5.6.1.Rest of Asia-Pacific Mouth Ulcers Treatment market, by drug class
7.4.5.6.2.Rest of Asia-Pacific Mouth Ulcers Treatment market, by formulation type
7.4.5.6.3.Rest of Asia-Pacific Mouth Ulcers Treatment market, by indication
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA Mouth Ulcers Treatment market, by drug class
7.5.3.LAMEA Mouth Ulcers Treatment market, by formulation type
7.5.4.LAMEA Mouth Ulcers Treatment market, by indication
7.5.5.Market size and forecast, by country
7.5.5.1.Brazil
7.5.5.1.1.Brazil Mouth Ulcers Treatment market, by drug class
7.5.5.1.2.Brazil Mouth Ulcers Treatment market, by formulation type
7.5.5.1.3.Brazil Mouth Ulcers Treatment market, by indication
7.5.5.2.Saudi Arabia
7.5.5.2.1.Saudi Arabia Mouth Ulcers Treatment market, by drug class
7.5.5.2.2.Saudi Arabia Mouth Ulcers Treatment market, by formulation type
7.5.5.2.3.Saudi Arabia Mouth Ulcers Treatment market, by indication
7.5.5.3.South Africa
7.5.5.3.1.South Africa Mouth Ulcers Treatment market, by drug class
7.5.5.3.2.South Africa Mouth Ulcers Treatment market, by formulation type
7.5.5.3.3.South Africa Mouth Ulcers Treatment market, by indication
7.5.5.4.Rest of LAMEA
7.5.5.4.1.Rest of LAMEA Mouth Ulcers Treatment market, by drug class
7.5.5.4.2.Rest of LAMEA Mouth Ulcers Treatment market, by formulation type
7.5.5.4.3.Rest of LAMEA Mouth Ulcers Treatment market, by indication
CHAPTER 8:COMPANY PROFILES
8.1.BLISTEX INC.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.2.BRISTOL-MYERS SQUIBB COMPANY
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.3.CHURCH & DWIGHT CO., INC.
8.3.1.Company overview
8.3.2.Operating business segments
8.3.3.Product portfolio
8.3.4.Business performance
8.3.5.Key strategic moves and developments
8.4.COLGATE-PALMOLIVE COMPANY
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.DR. REDDY’S LABORATORIES LIMITED
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.6.GLAXOSMITHKLINE PLC
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.7.PATTERSON COMPANIES, INC.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.8.PFIZER, INC.
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.9.PRINCE CARE PHARMA PVT LTD
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Product portfolio
8.10.3M COMPANY
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
TABLE 01.GLOBAL MOUTH ULCERS TREATMENT MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 02.ANALGESICS AND CORTICOSTEROIDS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 03.ANALGESICS AND CORTICOSTEROIDS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 04.MOUTH ULCERS TREATMENT MARKET FOR ANTIHISTAMINE, BY REGION, 2020-2030 ($MILLION)
TABLE 05.ANTIHISTAMINE MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 06.MOUTH ULCERS TREATMENT MARKET FOR ANTIMICROBIAL, BY REGION, 2020-2030 ($MILLION)
TABLE 07.ANTIMICROBIAL MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 08.MOUTH ULCERS TREATMENT MARKET FOR ANESTHETIC, BY REGION, 2020-2030 ($MILLION)
TABLE 09.ANESTHETIC MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 10.GLOBAL MOUTH ULCERS TREATMENT MARKET, BY FORMULATION TYPE, 2020-2030 ($MILLION)
TABLE 11.MOUTH ULCERS TREATMENT MARKET FOR SPRAYS, BY REGION, 2020-2030 ($MILLION)
TABLE 12.MOUTH ULCERS TREATMENT MARKET FOR MOUTHWASH, BY REGION, 2020-2030 ($MILLION)
TABLE 13.MOUTH ULCERS TREATMENT MARKET FOR GELS, BY REGION, 2020-2030 ($MILLION)
TABLE 14.MOUTH ULCERS TREATMENT MARKET FOR LOZENGES, BY REGION, 2020-2030 ($MILLION)
TABLE 15.GLOBAL MOUTH ULCERS TREATMENT MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 16.MOUTH ULCERS TREATMENT MARKET FOR APHTHOUS STOMATITIS, BY REGION, 2020-2030 ($MILLION)
TABLE 17.MOUTH ULCERS TREATMENT MARKET FOR ORAL LICHEN PLANUS, BY REGION, 2020-2030 ($MILLION)
TABLE 18.MOUTH ULCERS TREATMENT MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 19.MOUTH ULCERS TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 20.NORTH AMERICA MOUTH ULCERS TREATMENT MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 21.NORTH AMERICA MOUTH ULCERS TREATMENT MARKET, BY FORMULATION TYPE, 2020-2030 ($MILLION)
TABLE 22.NORTH AMERICA MOUTH ULCERS TREATMENT MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 23.NORTH AMERICA MOUTH ULCERS TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 24.U.S. MOUTH ULCERS TREATMENT MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 25.U.S. MOUTH ULCERS TREATMENT MARKET, BY FORMULATION TYPE, 2020-2030 ($MILLION)
TABLE 26.U.S. MOUTH ULCERS TREATMENT MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 27.CANADA MOUTH ULCERS TREATMENT MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 28.CANADA MOUTH ULCERS TREATMENT MARKET, BY FORMULATION TYPE, 2020-2030 ($MILLION)
TABLE 29.CANADA MOUTH ULCERS TREATMENT MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 30.MEXICO MOUTH ULCERS TREATMENT MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 31.MEXICO MOUTH ULCERS TREATMENT MARKET, BY FORMULATION TYPE, 2020-2030 ($MILLION)
TABLE 32.MEXICO MOUTH ULCERS TREATMENT MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 33.EUROPE MOUTH ULCERS TREATMENT MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 34.EUROPE MOUTH ULCERS TREATMENT MARKET, BY FORMULATION TYPE, 2020-2030 ($MILLION)
TABLE 35.EUROPE MOUTH ULCERS TREATMENT MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 36.EUROPE MOUTH ULCERS TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 37.GERMANY MOUTH ULCERS TREATMENT MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 38.GERMANY MOUTH ULCERS TREATMENT MARKET, BY FORMULATION TYPE, 2020-2030 ($MILLION)
TABLE 39.GERMANY MOUTH ULCERS TREATMENT MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 40.FRANCE MOUTH ULCERS TREATMENT MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 41.FRANCE MOUTH ULCERS TREATMENT MARKET, BY FORMULATION TYPE, 2020-2030 ($MILLION)
TABLE 42.FRANCE MOUTH ULCERS TREATMENT MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 43.UK MOUTH ULCERS TREATMENT MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 44.UK MOUTH ULCERS TREATMENT MARKET, BY FORMULATION TYPE, 2020-2030 ($MILLION)
TABLE 45.UK MOUTH ULCERS TREATMENT MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 46.ITALY MOUTH ULCERS TREATMENT MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 47.ITALY MOUTH ULCERS TREATMENT MARKET, BY FORMULATION TYPE, 2020-2030 ($MILLION)
TABLE 48.ITALY MOUTH ULCERS TREATMENT MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 49.SPAIN MOUTH ULCERS TREATMENT MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 50.SPAIN MOUTH ULCERS TREATMENT MARKET, BY FORMULATION TYPE, 2020-2030 ($MILLION)
TABLE 51.SPAIN MOUTH ULCERS TREATMENT MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 52.REST OF EUROPE MOUTH ULCERS TREATMENT MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 53.REST OF EUROPE MOUTH ULCERS TREATMENT MARKET, BY FORMULATION TYPE, 2020-2030 ($MILLION)
TABLE 54.REST OF EUROPE MOUTH ULCERS TREATMENT MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 55.ASIA-PACIFIC MOUTH ULCERS TREATMENT MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 56.ASIA-PACIFIC MOUTH ULCERS TREATMENT MARKET, BY FORMULATION TYPE, 2020-2030 ($MILLION)
TABLE 57.ASIA-PACIFIC MOUTH ULCERS TREATMENT MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 58.ASIA-PACIFIC MOUTH ULCERS TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 59.JAPAN MOUTH ULCERS TREATMENT MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 60.JAPAN MOUTH ULCERS TREATMENT MARKET, BY FORMULATION TYPE, 2020-2030 ($MILLION)
TABLE 61.JAPAN MOUTH ULCERS TREATMENT MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 62.CHINA MOUTH ULCERS TREATMENT MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 63.CHINA MOUTH ULCERS TREATMENT MARKET, BY FORMULATION TYPE, 2020-2030 ($MILLION)
TABLE 64.CHINA MOUTH ULCERS TREATMENT MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 65.AUSTRALIA MOUTH ULCERS TREATMENT MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 66.AUSTRALIA MOUTH ULCERS TREATMENT MARKET, BY FORMULATION TYPE, 2020-2030 ($MILLION)
TABLE 67.AUSTRALIA MOUTH ULCERS TREATMENT MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 68.INDIA MOUTH ULCERS TREATMENT MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 69.INDIA MOUTH ULCERS TREATMENT MARKET, BY FORMULATION TYPE, 2020-2030 ($MILLION)
TABLE 70.INDIA MOUTH ULCERS TREATMENT MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 71.SOUTH KOREA MOUTH ULCERS TREATMENT MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 72.SOUTH KOREA MOUTH ULCERS TREATMENT MARKET, BY FORMULATION TYPE, 2020-2030 ($MILLION)
TABLE 73.SOUTH KOREA MOUTH ULCERS TREATMENT MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 74.REST OF ASIA-PACIFIC MOUTH ULCERS TREATMENT MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 75.REST OF ASIA-PACIFIC MOUTH ULCERS TREATMENT MARKET, BY FORMULATION TYPE, 2020-2030 ($MILLION)
TABLE 76.REST OF ASIA-PACIFIC MOUTH ULCERS TREATMENT MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 77.LAMEA MOUTH ULCERS TREATMENT MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 78.LAMEA MOUTH ULCERS TREATMENT MARKET, BY FORMULATION TYPE, 2020-2030 ($MILLION)
TABLE 79.LAMEA MOUTH ULCERS TREATMENT MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 80.LAMEA MOUTH ULCERS TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 81.BRAZIL MOUTH ULCERS TREATMENT MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 82.BRAZIL MOUTH ULCERS TREATMENT MARKET, BY FORMULATION TYPE, 2020-2030 ($MILLION)
TABLE 83.BRAZIL MOUTH ULCERS TREATMENT MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 84.SAUDI ARABIA MOUTH ULCERS TREATMENT MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 85.SAUDI ARABIA MOUTH ULCERS TREATMENT MARKET, BY FORMULATION TYPE, 2020-2030 ($MILLION)
TABLE 86.SAUDI ARABIA MOUTH ULCERS TREATMENT MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 87.SOUTH AFRICA MOUTH ULCERS TREATMENT MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 88.SOUTH AFRICA MOUTH ULCERS TREATMENT MARKET, BY FORMULATION TYPE, 2020-2030 ($MILLION)
TABLE 89.SOUTH AFRICA MOUTH ULCERS TREATMENT MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 90.REST OF LAMEA MOUTH ULCERS TREATMENT MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 91.REST OF LAMEA MOUTH ULCERS TREATMENT MARKET, BY FORMULATION TYPE, 2020-2030 ($MILLION)
TABLE 92.REST OF LAMEA MOUTH ULCERS TREATMENT MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 93.BLISTEX: COMPANY SNAPSHOT
TABLE 94.BLISTEX: OPERATING SEGMENTS
TABLE 95.BLISTEX: PRODUCT PORTFOLIO
TABLE 96.BRISTOL-MYERS.: COMPANY SNAPSHOT
TABLE 97.BRISTOL-MYERS: OPERATING SEGMENTS
TABLE 98.BRISTOL-MYERS: PRODUCT PORTFOLIO
TABLE 99.CHURCH AND DWIGHT: COMPANY SNAPSHOT
TABLE 100.BIODIEM: OPERATING SEGMENTS
TABLE 101.CHURCH AND DWIGHT: PRODUCT PORTFOLIO
TABLE 102.COLGATE-PALMOLIVE: COMPANY SNAPSHOT
TABLE 103.COLGATE-PALMOLIVE: OPERATING SEGMENTS
TABLE 104.COLGATE-PALMOLIVE: PRODUCT PORTFOLIO
TABLE 105.DR. REDDY'S: COMPANY SNAPSHOT
TABLE 106.DR. REDDY'S LABORATORIES: OPERATING SEGMENTS
TABLE 107.DR. REDDY'S LABORATORIES: PRODUCT TYPE PORTFOLIO
TABLE 108.GLAXOSMITHKLINE.: COMPANY SNAPSHOT
TABLE 109.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 110.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 111.PATTERSON.: COMPANY SNAPSHOT
TABLE 112.PATTERSON COMPANIES: OPERATING SEGMENTS
TABLE 113.PATTERSON: PRODUCT TYPE PORTFOLIO
TABLE 114.PFIZER INC: COMPANY SNAPSHOT
TABLE 115.PFIZER: OPERATING BUSINESS SEGMENTS
TABLE 116.PFIZER INC: PRODUCT TYPE PORTFOLIO
TABLE 117.PRINCE CARE: COMPANY SNAPSHOT
TABLE 118.PRINCE CARE: PRODUCT TYPE PORTFOLIO
TABLE 119.3M: COMPANY SNAPSHOT
TABLE 120.3M: OPERATING SEGMENTS
TABLE 121.3M: PRODUCT TYPE PORTFOLIO
Complete report $6,100. DataPack (test volumes, sales forecasts, supplier shares) $3,950.
Summary
This comprehensive report contains 409 pages, 35 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the UK coagulation testing market duri...
Complete report $9,600. DataPack (test volumes, sales forecasts, supplier shares) $6,200.
Summary
This comprehensive report contains 424 pages, 37 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the US coagulation testing market during the...
This new report from VPGMarketResearch.com provides strategic assessments of major blood banking product suppliers and emerging market entrants. The report presents analyses of major current and emerging suppliers in terms of their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies.
Con...